Drug Trial Radar · NCT04349410
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
Last checked: Nov 19, 2026Latest source record: Nov 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,800
Actual
Start
Apr 11, 2020
Primary completion
Sep 14, 2020
Study completion Sep 14, 2020
Sponsor
- Lead sponsor
- The Camelot FoundationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Diagnostic determination of disease and treatment responses has been limited to qualitative imaging, measurement of serum markers of disease, and sampling of tissue. In each of these instances, there is a built in error either due to sensitivity and specificity issues, clinician interpretation of results, or acceptance of the use of an indirect marker (blood test) of what is happening elsewhere in the body - at the tissue level. The Fleming Method for Tissue and Vascular Differentiation and Metabolism (FMTVDM) using same state single or sequential quantification comparisons \[1\] provides the first and only patented test (#9566037) - along with the associated submitted patent applications ruled to be covered under #9566037 - that quantitatively measures changes in tissue resulting from inter alia a disease process. This includes inter alia coronary artery disease (CAD), cancer and infectious/inflammatory processes including CoVid-19 pneumonia (CVP) resulting from the metabolic and regional blood flow differences (RBFDs) caused by these diseases. The purpose of this paper is to make clinicians and researchers aware of this proposed method for investigating the prevalence and severity of CVP - in addition to providing rapid determination of treatment response in each patient, directing treatment decisions; thereby reducing the loss of time, money, resources and patient lives.
Conditions
- CoVid 19 Positive
Interventions
Hydroxychloroquine, AzithromycinDrug
FMTVDM Planar, SPECT, PET
Hydroxychloroquine, DoxycyclineDrug
FMTVDM Planar, SPECT, PET
Hydroxychloroquine, ClindamycinDrug
FMTVDM Planar, SPECT, PET
Hydroxychloroquine, Clindamycin, Primaquine - low dose.Drug
FMTVDM Planar, SPECT, PET
Hydroxychloroquine, Clindamycin, Primaquine - high dose.Drug
FMTVDM Planar, SPECT, PET
RemdesivirDrug
FMTVDM Planar, SPECT, PET
TocilizumabDrug
FMTVDM Planar, SPECT, PET
MethylprednisoloneDrug
FMTVDM Planar, SPECT, PET
Interferon-Alpha2BDrug
FMTVDM Planar, SPECT, PET
LosartanDrug
FMTVDM Planar, SPECT, PET
Convalescent SerumDrug
FMTVDM Planar, SPECT, PET
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in FMTVDM Measurement with nuclear imaging.Time frame: 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
FHHI-OI-Camelot; QME
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.